StockUK listing UK0QNDLSEHealthcareBalanced

Bachem Holding AG(0QND) Stock Analysis | Healthcare

GBP --+0.00%
Reward55Moderate
Risk37Moderate
75%Data
Strong 21% profit margin
GBP —+0.00 (+0.00%) Previous close · LSE
Market cap 936.11M
Reward Ratingⓘ55 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ37 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0QND to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Bachem Holding AG?

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.

AI Brief Pro

The brief on Bachem Holding AG

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Bachem Holding AG?

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 936.11M, and a P/E ratio of 51.8x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Profitability metrics are mixed — margins may be under pressure.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (55)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

All Healthcare stocks →
Company Information
IndustryBiotechnology
Market Cap936.11M
P/E Ratio51.8221
Beta0.792
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.